<DOC>
	<DOCNO>NCT01381172</DOCNO>
	<brief_summary>The objective investigation evaluate safety effectiveness OPTIMIZER® System subject medically refractory moderate-to-severe heart failure .</brief_summary>
	<brief_title>Evaluate Safety Efficacy OPTIMIZER® System Subjects With Moderate-to-Severe Heart Failure : FIX-HF-5C</brief_title>
	<detailed_description>The Impulse Dynamics FIX-HF-5C Study prospective , multicenter , randomize study evaluate safety efficacy cardiac contractility modulation ( CCM ) signal deliver implantable OPTIMIZER System patient NYHA class III IV heart failure ejection fraction 25-45 % . The study involve recruitment 160 subject total 60 site . Those subject fulfill inclusion exclusion criterion base upon baseline test result randomly assign 1:1 ratio either OPTIMIZER System plus optimal medical therapy ( OMT ) control group receive OMT alone . All randomized subject follow 24 week shall receive study related assessment throughout course study . In addition , subject continue receive OMT treatment heart failure . Mortality report 2 year .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Subjects 18 year age old 2 . Subjects either male female . Females childbearing potential must use medically approve method birth control must agree continue use birth control throughout study , must surgically sterilize ( tubal ligation , hysterectomy ) postmenopausal least 1 year . 3 . Condition 1 . Subjects baseline ejection fraction great equal 25 % less equal 45 % echocardiography determine echocardiography core laboratory . 2 . Subjects treat heart failure least 90 day ( include treatment βblocker least 90 day unless subject intolerant ) New York Heart Association functional Class III IV time enrollment . 3 . Subjects receive appropriate , stable medical therapy 30 day prior enrollment treatment heart failure accord region specific guideline recommendation . For patient EF≤35 % , regimen shall consist appropriate dos diuretic , ACEinhibitor angiotensin II receptor blocker βblocker . Stable define 100 % increase 50 % decrease dose . 4 . Subjects , opinion Principal Investigator ( base current guideline clinical practice ) , clinical indication implant cardiac defibrillator ( ICD , e.g. , EF≤35 % ) and/or pacemaker , must exist device agree undergo implantation device unless patient refuse undergo implantation device personal reason . 5 . Subjects willing able return followup visit . 1 . Subjects whose baseline peak VO2 &lt; 9 &gt; 20 ml O2/min/kg . 2 . Subjects potentially correctible cause heart failure , valvular heart disease congenital heart disease . 3 . Subjects clinically significant angina pectoris , consist angina daily life ( i.e. , Canadian Cardiovascular Society Angina score II ) , episode unstable angina within 30 day enrollment , angina and/or ECG change exercise test perform baseline evaluation . 4 . Subjects hospitalize heart failure require use inotropic support within 30 day enrollment . 5 . Subjects clinically significant amount ambient ectopy , define 8,900 PVCs per 24 hour baseline Holter monitoring . 6 . Subjects PR interval great 375 ms. 7 . Subjects chronic ( permanent persistent ) atrial fibrillation atrial flutter cardioverted within 30 day enrollment . 8 . Subjects whose exercise tolerance limited condition heart failure ( e.g. , angina , COPD , peripheral vascular disease , orthopedic rheumatologic condition ) unable perform baseline stress test . 9 . Subjects schedule CABG PTCA procedure , undergone CABG procedure within 90 day PTCA procedure within 30 day enrollment . 10 . Subjects biventricular pacing system , accept indication device , QRS width 130ms great . 11 . Subjects myocardial infarction within 90 day enrollment . 12 . Subjects mechanical tricuspid valve . 13 . Subjects prior heart transplant . 14 . Subjects dialysis . 15 . Subjects participate another experimental protocol . 16 . Subjects unable provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>Chronic heart disease</keyword>
	<keyword>Cardiac contractility modulation</keyword>
	<keyword>CCM</keyword>
	<keyword>CHF</keyword>
</DOC>